Diabetic retinopathyStatus:In development | In consultationProgramme:NICE guidelineConsultation end date: 27 September 2023Expected publication date: 2 February 2024
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder [ID5105]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 7 February 2024
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 1 May 2024
Pegcetacoplan for treating geographic atrophy [ID4041]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 12 June 2024
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 19 June 2024
Glaucoma - lerdelimumab (CAT-152) [ID383]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous treatment (Review of TA613) [ID6307]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC